SCHEMBL19472199

SCHEMBL19472199

O=c1oc2ccccc2c2cc(-n3c4ccccc4c4cc(-c5ccccc5)ccc43)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 5/20 0.42
▸ PLA2G4A P47712 5/20 0.42
▸ PLA2G10 O15496 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ NQO1 P15559 1/20 0.38
▸ TSPO P30536 1/20 0.37
▸ CA9 Q16790 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ ATM Q13315 1/20 0.36
▸ GABRP O00591 1/20 0.36
▸ GABRD O14764 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ TNKS O95271 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ ABCB1 P08183 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17637710 0.95 PLA2G2A (0.42) PLA2G2APLA2G4APLA2G10NPSR1RXFP1
SCHEMBL19472141 0.93 KDM4E (0.41) PLA2G2APLA2G4APLA2G10NPSR1RXFP1
SCHEMBL19472197 0.92 NPSR1 (0.45) PLA2G2APLA2G4ANPSR1RXFP1TSPO
SCHEMBL19472195 0.92 NPC1 (0.45) PLA2G2APLA2G4APLA2G10NPSR1RXFP1
SCHEMBL19472139 0.91 NPSR1 (0.40) PLA2G2APLA2G4APLA2G10NPSR1RXFP1
SCHEMBL17637842 0.91 NPSR1 (0.43) PLA2G2APLA2G4ANPSR1RXFP1CA9
SCHEMBL17637885 0.91 L3MBTL1 (0.46) PLA2G2APLA2G4APLA2G10NPSR1RXFP1
SCHEMBL17637780 0.91 NPSR1 (0.42) PLA2G2APLA2G4APLA2G10NPSR1RXFP1
SCHEMBL19472140 0.91 NPSR1 (0.41) PLA2G2APLA2G4ANPSR1RXFP1TSPO
SCHEMBL19472202 0.91 L3MBTL1 (0.43) PLA2G2APLA2G4APLA2G10NPSR1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197887-B1 HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2020-09-23 — — EP disclosed
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures MERCK PATENT GMBH (DE) 2019-08-13 — — US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 — — US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES NISCH, SIRT3, NQO1 PLA2G2A 4862/4885PLA2G4A 4861/4885PLA2G10 4856/4885
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures NISCH, SIRT3, NQO1 PLA2G2A 4862/4885PLA2G4A 4861/4885PLA2G10 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback